Evidence map›Paper›PMID 31885878›Full record

ArticleSignal transduction and targeted therapy

The β-catenin/YAP signaling axis is a key regulator of melanoma-associated fibroblasts.

Tianyi Liu, Linli Zhou, Kun Yang, Kentaro Iwasawa, Ana Luisa Kadekaro, Takanori Takebe, Thomas Andl, Yuhang Zhang

Open access · goldAbstract read
In one paragraph

Article in Signal transduction and targeted therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. BRAF mutation and tumor immune microenvironment in new era.American journal of cancer research · 2026
    Review
  8. PDPNCell communication and signaling : CCS · 2025
    Article
  9. Review
  10. Hippo/YAP signaling's multifaceted crosstalk in cancer.Frontiers in cell and developmental biology · 2025
    Review
  11. Review
  12. Cell signaling inFrontiers in cellular and infection microbiology · 2025
    Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Dual effect of vitamin DBMC cancer · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Tianyi Liu1Division of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267 USA.
Linli Zhou1Division of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267 USA.
Kun Yang1Division of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267 USA.
Kentaro Iwasawa2Division of Gastroenterology, Hepatology & Nutrition, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229-3039 USA.
Ana Luisa Kadekaro4Department of Dermatology, College of Medicine, University of Cincinnati, Cincinnati, OH 45267 USA.ORCID 0000-0003-4832-5958
Takanori Takebe2Division of Gastroenterology, Hepatology & Nutrition, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229-3039 USA.
Thomas Andl8Burnett School of Biological Sciences, University of Central Florida, Orlando, FL 32816 USA.
Yuhang Zhang1Division of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267 USA.ORCID 0000-0002-9738-5343
University of Cincinnati · USCincinnati Children's Hospital Medical Center · USTokyo Medical and Dental University · JPUniversity of Central Florida · USUniversity of Cincinnati Medical Center · US

Funding

LCenter for Clinical and Translational Science and TrainingUL1TR001425 · NCATS · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E., KISSELA, BRETT M · 2015 to 2024
$37.5M
Breaking down the matrix in the melanoma microenvironment: Mechanism and therapeutic evaluationR15CA228014 · NCI · UNIVERSITY OF CINCINNATI · PI ZHANG, YUHANG · 2018 to 2018
$481k
NCATS NIH HHS UL1 TR001425NCI NIH HHS R15 CA228014
6 · The paper itself

Abstract

β-catenin is a multifunctional protein that plays crucial roles in embryonic development, physiological homeostasis, and a wide variety of human cancers. Previously, we showed that in vivo targeted ablation of β-catenin in melanoma-associated fibroblasts after melanoma formation significantly suppressed tumor growth. However, when the expression of β-catenin was ablated in melanoma-associated fibroblasts before tumor initiation, melanoma development was surprisingly accelerated. How stromal β-catenin deficiency leads to opposite biological effects in melanoma progression is not completely understood. Here, we report that β-catenin is indispensable for the activation of primary human stromal fibroblasts and the mediation of fibroblast-melanoma cell interactions. Using coimmunoprecipitation and proximity ligation assays, we identified Yes-associated protein (YAP) as an important β-catenin-interacting partner in stromal fibroblasts. YAP is highly expressed in the nuclei of cancer-associated fibroblasts (CAFs) in both human and murine melanomas. Mechanistic investigation revealed that YAP nuclear translocation is significantly modulated by Wnt/β-catenin activity in fibroblasts. Blocking Wnt/β-catenin signaling in stromal fibroblasts inhibited YAP nuclear translocation. In the absence of YAP, the ability of stromal fibroblasts to remodel the extracellular matrix (ECM) was inhibited, which is consistent with the phenotype observed in cells with β-catenin deficiency. Further studies showed that the expression of ECM proteins and enzymes required for remodeling the ECM was suppressed in stromal fibroblasts after YAP ablation. Collectively, our data provide a new paradigm in which the β-catenin-YAP signaling axis regulates the activation and tumor-promoting function of stromal fibroblasts.

Indexed as

Cancer microenvironmentCell biology

Identifiers

PMID31885878
PMCPMC6928146
OpenAlexW2995270736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.